Shin Mineishi is an Oncology physician affiliated with Penn State Milton S. Hershey Medical Center. OpenAlex indexes 332 publications with 8,572 citations (h-index 47); ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
500 University Dr
Hershey, PA 170332360
Telephone
717-531-8401Registry record last updated 25 Jul 2016.
Clinical trials
- Pevonedistat and Azacitidine as Maintenance Therapy After Allogeneic Stem Cell Transplantation for Non-Remission AML
Sponsor: Milton S. Hershey Medical Center
- Multi-center Study of Myeloablative Allo Stem Cell Transplant for Non-remission AML Using CloBu4 Regimen
Sponsor: University of Michigan Rogel Cancer Center
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
16 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Astellas Pharma IncProgram year20251 payment
- Kite Pharma, Inc.Program year20251 payment
- Daiichi Sankyo Inc.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
57.3%Kinase inhibitor30%Jakafi67%Brukinsa23%Iclusig10%Part D<11 patientsThalidomide Analog10.7%Lenalidomide37%Pomalyst37%Revlimid27%Part D<11 patients+ 4 more classes in this area
Anti-infectives
19.3%Short-acting sulfonamides8.8%Sulfamethoxazole-Trimethoprim100%Part D≥15 patientsSulfone3.3%Dapsone100%Part D<11 patients+ 3 more classes in this area
Dermatology
9.8%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor9.8%Acyclovir100%Part D≥11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Gilteritinib as Post-Transplant Maintenance for AML With Internal Tandem Duplication Mutation of <i>FLT3</i>
Journal of Clinical Oncology
2024 - Dendritic Cell Regulation of Graft-Vs.-Host Disease: Immunostimulation and Tolerance
Frontiers in Immunology
2019 - Myeloablative Autologous Stem-Cell Transplantation for Severe Scleroderma
New England Journal of Medicine
2018
Similar KOLs
Other experts from the same institution or the same specialty.
Nancy Olsen, MD
Penn State Milton S. Hershey Medical Center
Michael Glantz, MD
Penn State Milton S. Hershey Medical Center
Joel Sorosky, MD
Penn State Milton S. Hershey Medical Center
Catharine Paules, MD
Penn State Milton S. Hershey Medical Center
Carl June, MD
University of Pennsylvania
Christopher Benz, MD
Buck Institute for Research on Aging
Christina Fitzmaurice, MD
Gundersen Health System
Beth Karlan, MD
Cedars-Sinai Medical Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”